Literature DB >> 22588949

Dietary energy balance modulates epithelial-to-mesenchymal transition and tumor progression in murine claudin-low and basal-like mammary tumor models.

Sarah M Dunlap1, Lucia J Chiao, Leticia Nogueira, Jerry Usary, Charles M Perou, Lyuba Varticovski, Stephen D Hursting.   

Abstract

Using novel murine models of claudin-low and basal-like breast cancer, we tested the hypothesis that diet-induced obesity (DIO) and calorie restriction (CR) differentially modulate progression of these aggressive breast cancer subtypes. For model development, we characterized two cell lines, "mesenchymal (M)-Wnt" and "epithelial (E)-Wnt," derived from MMTV-Wnt-1 transgenic mouse mammary tumors. M-Wnt, relative to E-Wnt, cells were tumor-initiating cell (TIC)-enriched (62% vs. 2.4% CD44(high)/CD24(low)) and displayed enhanced ALDEFLUOR positivity, epithelial-to-mesenchymal transition (EMT) marker expression, mammosphere-forming ability, migration, invasion, and tumorigenicity (P < 0.001; each parameter). M-Wnt and E-Wnt cells clustered with claudin-low and basal-like breast tumors, respectively, in gene expression profiles and recapitulated these tumors when orthotopically transplanted into ovariectomized C57BL/6 mice. To assess the effects of energy balance interventions on tumor progression and EMT, mice were administered DIO, control, or CR diets for 8 weeks before orthotopic transplantation of M-Wnt or E-Wnt cells (for each cell line, n = 20 mice per diet) and continued on their diets for 6 weeks while tumor growth was monitored. Relative to control, DIO enhanced M-Wnt (P = 0.01), but not E-Wnt, tumor progression; upregulated EMT- and TIC-associated markers including N-cadherin,fibronectin, TGFβ, Snail, FOXC2, and Oct4 (P < 0.05, each); and increased intratumoral adipocytes. Conversely, CR suppressed M-Wnt and E-Wnt tumor progression (P < 0.02, each) and inhibited EMT and intratumoral adipocyte accumulation. Thus, dietary energy balance interventions differentially modulate EMT and progression of claudin-low and basal-like tumors. EMT pathway components may represent targets for breaking the obesity-breast cancer link, particularly for preventing and/or controlling TIC-enriched subtypes such as claudin-low breast cancer. ©2012 AACR.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22588949      PMCID: PMC3822442          DOI: 10.1158/1940-6207.CAPR-12-0034

Source DB:  PubMed          Journal:  Cancer Prev Res (Phila)        ISSN: 1940-6215


  40 in total

1.  Tumor progression induced by the loss of E-cadherin independent of beta-catenin/Tcf-mediated Wnt signaling.

Authors:  M Herzig; F Savarese; M Novatchkova; H Semb; G Christofori
Journal:  Oncogene       Date:  2006-10-09       Impact factor: 9.867

2.  A mouse mammary tumor virus-Wnt-1 transgene induces mammary gland hyperplasia and tumorigenesis in mice lacking estrogen receptor-alpha.

Authors:  W P Bocchinfuso; W P Hively; J F Couse; H E Varmus; K S Korach
Journal:  Cancer Res       Date:  1999-04-15       Impact factor: 12.701

Review 3.  Use of MMTV-Wnt-1 transgenic mice for studying the genetic basis of breast cancer.

Authors:  Y Li; W P Hively; H E Varmus
Journal:  Oncogene       Date:  2000-02-21       Impact factor: 9.867

4.  Ob/ob serum promotes a mesenchymal cell phenotype in B16BL6 melanoma cells.

Authors:  Kyoko Kushiro; Nomelí P Núñez
Journal:  Clin Exp Metastasis       Date:  2011-08-31       Impact factor: 5.150

5.  Genetic reduction of insulin-like growth factor-1 mimics the anticancer effects of calorie restriction on cyclooxygenase-2-driven pancreatic neoplasia.

Authors:  Laura M Lashinger; Lauren M Malone; Mark J McArthur; Jason A Goldberg; Elizabeth A Daniels; Amy Pavone; Jennifer K Colby; Nicole C Smith; Susan N Perkins; Susan M Fischer; Stephen D Hursting
Journal:  Cancer Prev Res (Phila)       Date:  2011-05-18

6.  Obesity accelerates mouse mammary tumor growth in the absence of ovarian hormones.

Authors:  Nomeli P Nunez; Susan N Perkins; Nicole C P Smith; David Berrigan; David M Berendes; Lyuba Varticovski; J Carl Barrett; Stephen D Hursting
Journal:  Nutr Cancer       Date:  2008       Impact factor: 2.900

Review 7.  The basics of epithelial-mesenchymal transition.

Authors:  Raghu Kalluri; Robert A Weinberg
Journal:  J Clin Invest       Date:  2009-06       Impact factor: 14.808

8.  Obesity and risk of the less commonly diagnosed subtypes of breast cancer.

Authors:  A Stark; D Schultz; A Kapke; P Nadkarni; M Burke; M Linden; U Raju
Journal:  Eur J Surg Oncol       Date:  2009-01-01       Impact factor: 4.424

9.  Murine mammary tumor cells with a claudin-low genotype.

Authors:  Craig I Campbell; Devan E Thompson; Megan D Siwicky; Roger A Moorehead
Journal:  Cancer Cell Int       Date:  2011-08-16       Impact factor: 5.722

10.  Identification of conserved gene expression features between murine mammary carcinoma models and human breast tumors.

Authors:  Jason I Herschkowitz; Karl Simin; Victor J Weigman; Igor Mikaelian; Jerry Usary; Zhiyuan Hu; Karen E Rasmussen; Laundette P Jones; Shahin Assefnia; Subhashini Chandrasekharan; Michael G Backlund; Yuzhi Yin; Andrey I Khramtsov; Roy Bastein; John Quackenbush; Robert I Glazer; Powel H Brown; Jeffrey E Green; Levy Kopelovich; Priscilla A Furth; Juan P Palazzo; Olufunmilayo I Olopade; Philip S Bernard; Gary A Churchill; Terry Van Dyke; Charles M Perou
Journal:  Genome Biol       Date:  2007       Impact factor: 13.583

View more
  47 in total

Review 1.  Microbiome, bile acids, and obesity: How microbially modified metabolites shape anti-tumor immunity.

Authors:  Laura M Sipe; Mehdi Chaib; Ajeeth K Pingili; Joseph F Pierre; Liza Makowski
Journal:  Immunol Rev       Date:  2020-05       Impact factor: 12.988

2.  Obesity and Breast Cancer: A Complex Relationship.

Authors:  Victoria M Gershuni; Rexford S Ahima; Julia Tchou
Journal:  Curr Surg Rep       Date:  2016-03-21

Review 3.  The obesity-inflammation-eicosanoid axis in breast cancer.

Authors:  Linda Vona-Davis; David P Rose
Journal:  J Mammary Gland Biol Neoplasia       Date:  2013-10-30       Impact factor: 2.673

Review 4.  Minireview: the year in obesity and cancer.

Authors:  Stephen D Hursting
Journal:  Mol Endocrinol       Date:  2012-10-09

5.  Tumor-extrinsic discoidin domain receptor 1 promotes mammary tumor growth by regulating adipose stromal interleukin 6 production in mice.

Authors:  Xiujie Sun; Kshama Gupta; Bogang Wu; Deyi Zhang; Bin Yuan; Xiaowen Zhang; Huai-Chin Chiang; Chi Zhang; Tyler J Curiel; Michelle P Bendeck; Stephen Hursting; Yanfen Hu; Rong Li
Journal:  J Biol Chem       Date:  2018-01-03       Impact factor: 5.157

Review 6.  The Role of Adipokines in Breast Cancer: Current Evidence and Perspectives.

Authors:  Gerasimos Socrates Christodoulatos; Nikolaos Spyrou; Jona Kadillari; Sotiria Psallida; Maria Dalamaga
Journal:  Curr Obes Rep       Date:  2019-12

Review 7.  Obesity, energy balance, and cancer: new opportunities for prevention.

Authors:  Stephen D Hursting; John Digiovanni; Andrew J Dannenberg; Maria Azrad; Derek Leroith; Wendy Demark-Wahnefried; Madhuri Kakarala; Angela Brodie; Nathan A Berger
Journal:  Cancer Prev Res (Phila)       Date:  2012-10-03

8.  IGF1R inhibition in mammary epithelia promotes canonical Wnt signaling and Wnt1-driven tumors.

Authors:  Lauren M Rota; Lidia Albanito; Marcus E Shin; Corey L Goyeneche; Sain Shushanov; Emily J Gallagher; Derek LeRoith; Deborah A Lazzarino; Teresa L Wood
Journal:  Cancer Res       Date:  2014-08-04       Impact factor: 12.701

Review 9.  Deconvoluting the obesity and breast cancer link: secretome, soil and seed interactions.

Authors:  Nikki A Ford; Kaylyn L Devlin; Laura M Lashinger; Stephen D Hursting
Journal:  J Mammary Gland Biol Neoplasia       Date:  2013-10-04       Impact factor: 2.673

10.  Stearoyl gemcitabine nanoparticles overcome obesity-induced cancer cell resistance to gemcitabine in a mouse postmenopausal breast cancer model.

Authors:  Rebecca E De Angel; Jorge M Blando; Matthew G Hogan; Michael A Sandoval; Dharmika S P Lansakara-P; Sarah M Dunlap; Stephen D Hursting; Zhengrong Cui
Journal:  Cancer Biol Ther       Date:  2013-01-28       Impact factor: 4.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.